1. Home
  2. Clinical Topics
  3. Cardio-Pulmonary
  4. FDA approves treatment for two rare diseases
Cardio-PulmonaryClinical TopicsDrugs and DevicesWeb Exclusives

FDA approves treatment for two rare diseases

Share

On May 6, the FDA approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than 17 years of age. On the same date, the agency approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis in adults. 

Read more here and here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts